Inhibrx Gross Margin 2020-2022 | INBX
Current and historical gross margin for Inhibrx (INBX) over the last 10 years. The current gross profit margin for Inhibrx as of March 31, 2022 is %.
| Inhibrx Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2022-03-31 | $0.01B | $0.01B | 100.00% |
| 2021-12-31 | $0.01B | $0.01B | 100.00% |
| 2021-09-30 | $0.01B | $0.01B | 100.00% |
| 2021-06-30 | $0.01B | $0.01B | 100.00% |
| 2021-03-31 | $0.01B | $0.01B | 100.00% |
| 2020-12-31 | $0.01B | $0.01B | 100.00% |
| 2020-06-30 | $0.01B | $0.01B | 100.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.452B | $0.007B |
| Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $163.597B | 9.95 |
| Bio-Rad Laboratories (BIO.B) | United States | $14.907B | 32.33 |
| QIAGEN (QGEN) | Netherlands | $10.865B | 17.15 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.248B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.228B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.901B | 48.18 |
| Emergent Biosolutions (EBS) | United States | $1.599B | 6.85 |
| Myovant Sciences (MYOV) | United Kingdom | $1.236B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.320B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.114B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.104B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.103B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.087B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
